Spyre Therapeutics Inc (SYRE) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.15, surpassing Wall Street's consensus estimate of $-0.76 by $0.61. Revenue remained at $0.0B, aligning with analyst expectations.
This update provides insight into Spyre's operational performance and financial health. The positive earnings report may reflect stronger business fundamentals than previously anticipated.
The company, headquartered in Waltham, Massachusetts, focuses on developing next-generation human enzyme therapeutics aimed at addressing rare and high-burden diseases. Spyre's advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody targeting the a4b7 integrin, currently in development for treating inflammatory bowel disease (IBD). The firm also has several pipeline programs, including SPY002, SPY003, and others, which are in various stages of development.
Management will host an earnings conference call to discuss these results and provide further commentary on business performance. Investors are encouraged to review the full earnings release and listen to this commentary for complete context on the quarter’s performance and future outlook.
Upcoming earnings are scheduled for August 2, 2026, with an estimated EPS of $-0.7971 and revenue also estimated at $0.0B.